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Abstract Transglutaminases (TG) form a family of
enzymes that catalyse various post-translational modifica-
tions of glutamine residues in proteins and peptides including
intra- and intermolecular isopeptide bond formation, esteri-
fication and deamidation. We have characterized a novel
member of the mammalian TG family, TG6, which is
expressed in a human carcinoma cell line with neuronal
characteristics and in mouse brain. Besides full-length pro-
tein, alternative splicing results in a short variant lacking the
second b-barrel domain in man and a variant with truncated
b-sandwich domain in mouse. Biochemical data show that
TG6 is allosterically regulated by Ca2? and guanine nucle-
otides. Molecular modelling indicates that TG6 could have
Ca2? and GDP-binding sites related to those of TG3 and TG2,
respectively. Localization of mRNA and protein in the mouse
identified abundant expression of TG6 in the central nervous
system. Analysis of its temporal and spatial pattern of
induction in mouse development indicates an association
with neurogenesis. Neuronal expression of TG6 was con-
firmed by double-labelling of mouse forebrain cells with cell
type-specific markers. Induction of differentiation in mouse
Neuro 2a cells with NGF or dibutyryl cAMP is associated
with an upregulation of TG6 expression. Familial ataxia has
recently been linked to mutations in the TGM6 gene. Auto-
antibodies to TG6 were identified in immune-mediated ataxia
in patients with gluten sensitivity. These findings suggest a
critical role for TG6 in cortical and cerebellar neurons.
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Abbreviations
CNS Central nervous system
DIG Digoxigenin
GFAP Glial fibrillary acidic protein
HD Huntington’s disease
PCR Polymerase chain reaction
RT Reverse transcription
SCA Spinocerebellar ataxia
TG Transglutaminase
Introduction
Transglutaminases (TG) are a family of structurally and
functionally related enzymes that post-translationally
modify proteins by catalysing a Ca2?-dependent transfer-
ase reaction between the c-carboxamide group of a
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peptide-bound glutamine residue and various primary
amines. Most commonly, intra- or intermolecular c-glut-
amyl-e-lysine crosslinks are formed by reaction with the
e-amino group of a lysine residue (Folk and Chung 1973).
The action of these enzymes consequently results in the
formation of covalently crosslinked, often insoluble supra-
molecular structures and has a well-established role in
tissue homeostasis in many biological systems (Aeschlimann
and Thomazy 2000; Lorand and Graham 2003; Iismaa
et al. 2009). Besides crosslinking, peptide-bound glutamine
residues may be modified by TG through reaction of the
acyl-enzyme intermediate with low-molecular-weight
metabolites harbouring amino groups, or through hydro-
lysis or esterification. Conversion through hydrolysis is
comparably slow and occurs preferentially at pH \ 6.5.
Nevertheless, the biological significance of enzymatic
deamidation of glutamine has been illustrated by its role in
T-cell activation in celiac disease (Molberg et al. 1998;
Van de Wal et al. 1998). Transamidation has profound
effects on the biological activity of many substrate proteins
and it has become clear that some TGs preferentially form
intermolecular crosslinks, whereas others catalyse primar-
ily intramolecular reactions (Candi et al. 1995). Such
protein modifications can be dynamic as conversion of the
acyl-enzyme intermediate to the isopeptide bond is
reversible (Parameswaran et al. 1997). TGs are evolution-
arily related to papain-like cysteine proteases, both in terms
of the structure of the core domain and the mechanism of
catalysis, and more distantly to the peptide N-glycanases.
Other enzymes have evolved in lower species that can
catalyse the same transamidation reaction. These, however,
bear no genetic relationship to the TG genes in man and the
mechanism of catalysis is distinct, although it depends on a
reactive thiol in the enzyme active site. These include
Streptomyces microbial TG, bacterial toxins (including
cytotoxic necrotizing factor from E. coli and dermone-
crotic toxin from Bordetella), and thioredoxin/protein-dis-
ulfide isomerase-like enzymes from primitive eukaryotes
(e.g. ERp60-like from nematodes and PDI from Giardia).
Nine different TG genes have been characterized in
mammals (Aeschlimann and Paulsson 1994; Aeschlimann
et al. 1998; Grenard et al. 2001). They exhibit a similar
overall organization, with remarkable conservation of
intron distribution and intron splice types. Detailed com-
parison of the structure of the individual genes shows that
they may be divided into two subclasses, wherein the
TGM2-7 and EBP42 genes contain 13 exons, and the
F13A1 and TGM1 genes contain 15 exons (Grenard et al.
2001). Exon 9 of the former group is separated into two
exons, 10 and 11, in the TGM1 and F13A1 genes, and the
non-homologous N-terminal extensions of factor XIII
a-subunit and TG1 that are absent in other TGs are com-
prised by an additional exon. Several TG gene products
have been characterized in detail using a combination of
mutagenesis and structural studies to elucidate the enzy-
matic mechanism and its regulation. The three-dimensional
structures of three TGs have been solved, i.e. factor XIII a
(Yee et al. 1994), TG2 (Liu et al. 2002) and TG3 (Ahvazi
et al. 2002). All comprise of four domains that are similar
in organization: an amino terminal b-sandwich domain
which forms a functional unit with the core domain; the
catalytic core domain that contains the conserved active
site triad cysteine, histidine and aspartate residues; and two
C-terminal b-barrel domains which are involved in the
regulation of enzyme activity. Molecular modelling and
docking studies on TG3 proposed that binding of two
additional Ca2? ions converts the enzyme to the active
form on the approach of the first substrate (glutamine-
containing polypeptide) (Ahvazi et al. 2004). A recent
X-ray structure of a trapped transamidation intermediate of
TG2 (Pinkas et al. 2007) explained for the first time how a
crosslinked protein complex could be released from the
enzyme after catalysis as well as the considerable increase
in radius of gyration observed by small-angle X-ray scat-
tering for activated TG2 in solution (Mariani et al. 2000).
TG2 undergoes a large conformational change whereby the
b-barrel domains are rotated almost 180 into the plane of
the other two domains, thereby exposing the enzyme active
site (Pinkas et al. 2007).
TGs have been implicated in the pathogenesis of several
neurodegenerative diseases (polyglutamine expansion dis-
eases, Alzheimer’s, Parkinson’s and supranuclear palsy),
but despite extensive investigation over at least two dec-
ades ambiguity remains as to the physiological function of
TGs in the central nervous system (CNS) as well as their
role in pathogenesis (for review see Iismaa et al. 2009;
Jeitner et al. 2009). It has been shown that pathological
length CAG expansions are excellent substrates for TG2
and that TG2 activity is increased in the brains of patients
with Huntington’s disease (HD) and certain forms of spi-
nocerebellar ataxia (SCA) (Lesort et al. 1999). In Alzhei-
mer’s disease TGs have been localised to plaques and
tangles and these contain substrates of TG2 (Kim et al.
1999). Similarly, the presence of TG crosslinked a-syn-
uclein in substantia nigra dopaminergic neurons of Par-
kinson’s disease patients has been demonstrated (Andringa
et al. 2004). The fact that increased levels of the c-glut-
amyl-e-lysine crosslink as well as bis-c-glutamylpolyamine
are found in the affected tissue and in the cerebrospinal
fluid (Zainelli et al. 2003; Nemes et al. 2004; Jeitner et al.
2008) indicates that TG2 and possibly other TG isozymes
extensively modify proteins and possibly also disease-
specific protein aggregates. Mouse models have sub-
stantiated a direct role of TG2 in the pathogenesis of
Huntington’s and other neurodegenerative diseases albeit
the mechanisms involved being somewhat unexpected. HD
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mice (R6/1 and R6/2) lacking TG2 exhibit delayed mor-
tality and behavioural deficits but have increased aggregate
formation (Mastroberardino et al. 2002; Bailey and John-
son 2005). It is therefore possible that TG2 contributes to
the pathogenesis by modulating the size of the aggregates
formed, leading to the formation of smaller aggregates (Lai
et al. 2004) that may be more neurotoxic. In an Alzhei-
mer’s disease model, fibrillar Ab triggers dimerization of
angiotensin II type 2 receptors (AT2) which becomes a
substrate for TG2 and is further oligomerized (AbdAlla
et al. 2009). AT2 oligomerization results in sequestration of
Gaq/11 G protein which impairs M1 muscarinic receptor
function. Excitotoxic neuronal cell death is an important
component of acute injury in the CNS and also chronic
neurodegenerative diseases. Tissue-specific overexpression
of TG2 in mice sensitizes hippocampal neurons to apop-
tosis upon glutamate receptor overstimulation (Tucholski
et al. 2006) and ischemic injury induces rapid upregulation
of TG2 expression (Ientile et al. 2004) consistent with its
regulation by acute-phase injury cytokines. A recent study
provides evidence that TG2 has a broad effect on gene
transcription by regulating chromatin structure through
N-terminal polyamination of histone H3 in a model of HD
and that TG2 inhibition protects striatal neurons from
NMDA-mediated toxicity (McConoughey et al. 2010).
Inflammation is a component of neurodegenerative dis-
eases including HD and mediators such as TNFa may play
a critical role in upregulating TG2 expression locally.
Cytokine-mediated TG2 induction in astrocytes has been
shown for acute spinal cord injury (Monsonego et al. 1998)
and MS lesions (van Strien et al. 2011). It has also become
clear that there is significant complexity in the regulation
of TG activity in the CNS. Two TG2 variants in addition to
the full-length protein have been described in brain
(Monsonego et al. 1998; Citron et al. 2002; Antonyak et al.
2006; Tee et al. 2010). These result from alternative
splicing, giving rise to truncated proteins essentially lack-
ing either b-barrel 2 or both b-barrel domains and having
unique short C-terminal sequences. Expression of these
variants causes distinct changes in regulation of cell dif-
ferentiation and survival as a consequence of differences in
GTP binding of the variant proteins (Antonyak et al. 2006;
Tee et al. 2010). Although the major contribution to TG
activity in the CNS, and cerebral cortex in particular, has
been ascribed to TG2 (Bailey and Johnson 2004), c-glut-
amyl-e-lysine crosslinks are formed in TG2-/- brain
(Mastroberardino et al. 2002). Abundant expression of at
least two other TG isozymes, TG1 and TG3, in the CNS
has been shown (Kim et al. 1999), but the functional
importance of this remains to be investigated. Here we
characterize the hitherto uncharacterized TGM6 gene
product and discuss it in the wider context of CNS
development.
Materials and methods
Detailed descriptions of experimental procedures are given
in ‘‘Supplemental Material’’.
Cell culture
H69 cells (American Type Culture Collection) were main-
tained as floating cell aggregates at a density of
6–30 9 104 cells/ml in RPMI 1640 medium supplemented
with 10% heat-inactivated foetal calf serum (FCS) containing
100 units/ml penicilin and 100 lg/ml streptomycin. HEK293-
EBNA cells were grown in DMEM:Ham’s F-12 medium (1:1)
supplemented with 10% FCS, 250 lg/ml G418 (Invitrogen)
and antibiotics. Neuro 2a cells (European Collection of Cell
Cultures) were maintained in high-glucose DMEM supple-
mented with 10% FCS and antibiotics. For differentiation,
cells were seeded at 5,000 cells/cm2 in 24-well plates and
stimulated for 3 days by reducing FCS to 0.5% and where
indicated, adding 50 ng/ml NGF (Millipore), 1 mM dibutyryl
cAMP (Sigma), or 10 lM retinoic acid (Sigma).
Cloning of human TG6
Overlapping fragments (corresponding to nucleotides
71–502, 409–876, 705–1,442, 1,369–1,720 and 1,666–2,292
in AF540969) of TG6 were amplified by RT-PCR from H69
poly(A)?RNA. The 50-end of the cDNA was isolated by
50-RACE PCR as described (Grenard et al. 2001) and the
transcription initiation site determined by primer extension. A
full-length cDNA for TG6 was constructed by subcloning the
overlapping fragments as described (Hadjivassiliou et al.
2008). The full-length cDNA encoding TG6-L or TG6-S was
subcloned into the pCEP-4 vector for expression in HEK293
EBNA cells (Smyth et al. 2000). Cell strains stably expressing
TG6 were generated by transfection with lipofectamine (10 ll
for 2 lg plasmid DNA) and selection with puromycin, starting
with 0.5 lg/ml puromycin after 48 h and gradually increasing
to 10 lg/ml over a 10 day period.
Northern blotting
5 lg of H69 cell poly(A)?RNA was separated in a 1.2%
agarose gel, transferred to a nylon membrane and probed
with a digoxigenin(DIG)-UTP-labelled single-stranded
RNA probe corresponding to nucleotides 1,484–2,212
(AF540969) of TG6.
Analysis of TG expression in mouse brain and cloning
of mouse TG6
For cloning of mouse TG6, we prepared cDNA from
BALB/c brain and used a series of gene-specific
Transglutaminase 6 163
123
oligonucleotides modelled from the human TG6 sequence
to isolate overlapping DNA fragments by PCR. The 50-end
of the sequence was determined using 50-RACE PCR and
yielded besides the full-length mTG6 sequence a transcript
with an alternative exon 1 (AY177607). Real-time PCR to
quantify TG6 mRNA expression was carried out on an ABI
7700 Sequence Detection System using the 50 nuclease
assay with primers 50-CAGCAGTGGTAGGAGTGAC
AG (300 nM) and 50-CTCTTGGAAGGGGTTATGTTG
(600 nM) and labelled (50 6-carboxyfluorescein and 30
6-carboxytetramethylrhodamine) probe 50-CAAGGACAG
CTAAGTATTGAGGTGCCCAG. Reaction conditions
were as previously described except using 4 mM MgCl2
(Stephens et al. 2004).
Molecular modelling
A three-dimensional model of human TG6 was generated
using ProMod II (version 3.70 SP3; Arnold et al. 2006)
with the X-ray derived coordinates of human TG3 in its
activated form (Protein Data Bank code 1L9N, chain A;
Ahvazi et al. 2002) and the GDP-bound form of TG2
(1KV3, chain C; Liu et al. 2002) as a template resulting in
final total energies of -32,300 and -17,400 kJ/mol,
respectively, after optimizing the alignment manually.
ELISA style transamidation assay
TG activity was determined by measurement of the
incorporation of biotin-x-cadaverine (Molecular Probes)
into N,N-dimethylcasein immobilized on the surface of
protein binding 96-well plates essentially as described
(Kleman et al. 1995).
Real-time fluorescence assay for determination of TG
isopeptidase activity
The effect of nucleotides on TG activity [human TG6
(T021; Zedira) or TG2] was quantified by measuring
changes in fluorescence intensity over time at 37C as a
result of cleavage of Abz-APE(c-cad-Dnp)QEA (A102;
Zedira) in the presence of different concentrations of GTP,
GTPcS, GDP, GMP and ATP (Sigma). Fluorescence in the
absence of enzyme activation (no Ca2?) was subtracted and
reaction rates derived by linear regression. To obtain
steady-state kinetics for the replacement reaction, acyl
donor substrate concentration was varied from 3.2 to
170 lM. Product concentration was derived from a con-
centration series of Abz-APQQEA. The kinetic parameters
vmax and KM were obtained through nonlinear regression
[v = (vmax S)/(KM ? S)] and kcat calculated using
kcat = vmax/E0. All experiments were performed at least
twice independently.
In situ hybridization and immunolabelling of mouse
tissue
Sagittal sections of adult BALB/c mouse brain or mouse
embryos at different stages of gestation (E9–E16 and P0)
were hybridized to DIG-labelled 325 bp sense and anti-
sense RNA probes corresponding to the transcript region
encoding the TG6 b-barrels. Binding of the probes was
detected using alkaline phosphatase-conjugated anti-DIG
antibodies and visualized with NBT/BCIP. Polyclonal
antibodies to TG6 were raised in goat against a peptide
comprising residues 482–492 of mouse TG6 conjugated to
hemocyanin (Hadjivassiliou et al. 2008) and affinity puri-
fied over a thiol Sepharose column bearing disulphide-
linked peptide CGWRDDLLEPVTKPS as described
(Aeschlimann and Paulsson 1991). The sequence of this
loop connecting the catalytic core and b-barrel 1 domain is
shared among all TG6 splice variants but highly divergent
between different TGs. The absence of cross-reactivity
with other TG isozymes was established (Hadjivassiliou
et al. 2008). Immunolabelling for TG6 (1 lg/ml) and
b-tubulin III (Sigma T3952, 1:50 diluted) was performed as
previously described using HRP-conjugated secondary
antibodies and AEC (3-amino-9-ethyl carbazole) as a
substrate (Aeschlimann et al. 1993).
Isolation and differentiation of cortical progenitor cells
Cerebral cortex of newborn Balb/c mice was dissected on
ice in Hanks’ balanced salt solution (HBSS) and digested
for 20 min at 37C in 0.1% trypsin, 0.05% DNAse I
(Sigma) in HBSS. The tissue was washed and subsequently
triturated in HBSS/DNAse I solution to dissociate cells.
Cells were washed and subsequently maintained in
DMEM/F12 containing 2% B27 supplement (Invitrogen).
Number of vital cells was determined by trypan blue
exclusion. For FACS analysis, cells were washed in 0.5%
BSA in phosphate-buffered saline, pH 7.4 (PBS), filtered
through 40 lm Falcon cell strainers (Becton–Dickinson) to
remove remaining aggregates, fixed in 2% paraformalde-
hyde in PBS for 20 min on ice, permeabilized and stained
with antibodies to TG6 (20 lg/ml) and cell lineage mark-
ers, glial fibrillary acidic protein (G-A-5, Sigma; 15 lg/ml),
b-tubulin III (SDL.3D10, Sigma; 20 lg/ml) and RIP
(Chemicon, 1:1,000 diluted). For culture (formation of
neurospheres), medium was supplemented with 20 ng/ml
FGF2 (R&D Systems), 20 ng/ml EGF (Sigma) and anti-
biotics and 1 9 106 cells seeded into 35 mm hydrophobic
plastic dishes. For immunocytochemistry, cells were see-
ded at a density of 1 9 105 cells/well in a 12-well plate on
laminin-111 coated [purified from EHS tumour (Aeschli-
mann and Paulsson 1991)] cover slips and grown for
5 days. Cells were fixed in 4% paraformaldehyde,
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permeabilized and labelled with antibodies to TG6 and cell
lineage markers.
Protein analysis
Protein concentrations were determined using the
bicinchoninic acid reagent (Pierce) as described by the
supplier with BSA as a standard. For immunoblotting, pro-
teins were separated on 4–20% SDS–PAGE Tris–glycine
gels under reducing conditions (1% 2-mercaptoethanol),
transferred onto nitrocellulose membranes and stained with
antibodies as described (Aeschlimann et al. 1993).
Results and discussion
TG6 cloning and primary structure
We have previously identified a cluster of TG genes in the
human and mouse genome that contained a novel gene now
termed TGM6 (Grenard et al. 2001). We used RT-PCR to
screen different human cell lines for expression of the
respective gene product. TG6 (previously called TGY)
could not be detected in cells of a wide variety of origins
including mesenchymal, epithelial and hematopoietic cells
suggesting that it has a restricted expression pattern, but its
expression could be verified in a lung small cell carcinoma
cell line, H69, both by RT-PCR and Northern blotting
(Fig. 1a).
A full-length cDNA sequence for TG6 was obtained by
PCR using oligo(dT) primed cDNA from H69 cells and a
series of sequence specific primers based on the presumed
transcribed genomic sequence (Supplemental Fig. 1).
50-RACE PCR was used to identify the position of exon 1
which contains essentially non-coding sequence and
therefore shows no apparent similarity between different
TG genes. Primer extension was used to identify the 50-end
of the cDNA and this located the major transcription ini-
tiation site 455 nt upstream of the translation start codon
(Supplemental Fig. 2). The likely 30-end of the TG6 tran-
script may be inferred from an EST sequence in Gen-
BankTM (AA961594). Based on this, a polyadenylation
signal (ATAAA) could be located 3,887 nt downstream of
the termination codon. This is preceded by a CFIm-binding
site (TGTAA) and followed by a GT-rich sequence known
to bind CstF and therefore conforms to the tripartite ele-
ment required for efficient 30 RNA processing (Venkatar-
aman et al. 2005). The estimated size of the mRNA is
therefore 6,480–6,490 nt which is in good agreement with
the 6.3 kb transcript detected by Northern blotting
(Fig. 1a). A prominent band at *2.2 kb could indicate that
a short transcript may also be abundant but the exact nature
of that remains to be investigated. The obtained sequence
for full-length human TG6 contained an open reading
frame of 2,120 nt. The deduced protein consists of 706
amino acids and has a calculated molecular mass of
79,276 Da. This mass is in good agreement with the size
of the single protein band detected by Western blotting of
keratinocyte protein extract (natively expressed protein) or
when overexpressed in HEK293 cells after transfection
with a TG6 expression construct (Fig. 1d). Recombinant
enzyme displayed Ca2?-dependent transamidation activity
(Fig. 1e).
A shorter transcript which apparently resulted from
alternative splicing of the sequence encoded by exon 12
was also isolated from H69 cells (Fig. 1b). The absence of
exon 12 results in a frame shift and thereby in premature
termination within exon 13 (Supplemental Fig. 3). The
sequence for the short form of TG6 (TG6-S) encoded a
protein consisting of 625 amino acids (Mr 70,480, calcu-
lated). The TG6-S sequence terminates just after the first
C-terminal b-barrel domain and has a unique 14 amino acid
C-terminus (Fig. 1c). Overexpression in HEK293 cells
gives rise to a stable protein of expected size (Fig. 1d)
suggesting that this alternative splicing event may have
biological significance. The b-barrel domains have been
implicated in the regulation of enzyme-substrate interac-
tion and may also be involved in intracellular signalling as
a sequence within the second b-barrel domain of TG2 is
required for binding of PLCd1 (Hwang et al. 1995).
The H69 cell line displays neuronal characteristics
including expression of neuron-specific enolase, brain
isozyme of creatine kinase and L-dopa decarboxylase. We
therefore reasoned that TG6 may be expressed in neurons.
RT-PCR confirmed TG6 expression in mouse brain (see
below). The cDNA sequence for mouse TG6 was isolated
from brain, essentially using the same approach as for
human (Supplemental Fig. 1). We have not determined the
transcription initiation site. However, an EST sequence in
GenBankTM (BY357397) derives from the genomic
sequence upstream of the sequence we have isolated by
RACE PCR indicating that transcription may be initiated at
a position 389 nt upstream of the start codon, a position
similar to that in the human gene in the aligned sequences.
Two consecutive polyadenylation signals are present
1,096 nt downstream of the termination codon (Supple-
mental Fig. 1). Mouse and human TG6 have an 85%
identity on the amino acid level.
Cloning identified two splice variants in mouse brain
lacking either exon 3 or exon 3 together with exon 4
(Fig. 1c). Alternative splicing of exon 3 has been described
by us and others for several TG genes including TG2, TG4,
TG5 and band 4.2 protein and results in a TG with an
altered N-terminal b-sandwich domain (Cohen et al. 1993;
Aeschlimann et al. 1998; Candi et al. 2001; Cho et al.
2010; AK295775 in GenBankTM). TG5 lacking exon 3 has
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no transamidase activity (Candi et al. 2001). Omission of
exon 3 and 4 results in a frame shift and premature ter-
mination before the sequence encoding the catalytic core
domain, giving rise to a hypothetical 66 amino acid poly-
peptide without TG activity.
We could not detect alternative splicing of exon 12 in
mouse brain or neuroblastoma cells. An identical sequence
to H69 cell TG6-S was recently isolated from another
cancer cell suggesting that this splice variant may be
associated with oncogenic transformation. Four distinct
C-terminally truncated versions of TG2 have been identi-
fied. Variants resulting from retention of intron 10 and 6,
respectively, have been isolated from human disease states
(Fraij et al. 1992; Citron et al. 2002). The former, TG2-S,
results in a protein truncated within the sequence encoding
b-barrel 1. Another TG2 short form resulting from splicing
at an alternative 30 site within exon 12 and 50 acceptor site
within exon 13 retains b-barrel 1 but has a distinct short
C-terminal sequence (Monsonego et al. 1998; Citron et al.
2002). This variant was originally identified in rat astro-
cytes, but similar variants, TG2-V1 and TG2-V2, resulting
from use of two alternative 50 acceptor sites within exon 13
have subsequently been demonstrated in different human
primary cells (Lai et al. 2007). However, in mouse brain no
alternatively spliced variants of TG2 could be identified
(Citron et al. 2005). Alternative splicing of exon 11 in
human TG5 gives rise to a variant truncated within b-barrel
1 analogous to TG2-S (Candi et al. 2001). C-terminal
truncation affects allosteric regulation of TG2 by GTP and
has profound effects on cell differentiation and survival
(Monsonego et al. 1998; Antonyak et al. 2006; Tee et al.
2010).
TG6 is a very low abundant transcript as indicated from
directly analysing expression in specific cells and tissues as
well as from whole genome expression profile studies. For
mouse, the GenBankTM database contains a total of 21
independent ESTs. 18 of these are derived from skin and 1
each from retina and brain cortex. EST BB612839 is the
splice variant lacking exon 3 and 4. For man, there is only a
single EST from a lung small cell carcinoma. As a com-
parison, for TG2 the UniGeneTM EST profile lists over
29,000 ESTs in normal human tissues alone.
TG6 origin in evolution
Alignment of TG sequences selected to represent major
branches of animal evolution (Fig. 1f) indicates that the
invertebrate and low chordata proteins are most closely
related to the vertebrate isoforms TG4 and TG1. The factor
XIII a-subunit derives from the same branch as TG1. The
band 4.2 proteins show large divergence between species
indicating low evolutionary pressure for conservation. In
contrast to the mammalian and amphibian sequences, the
three reported avian band 4.2 sequences do contain the
catalytic triad residues indicating that these proteins may
function as active enzyme. Within the vertebrate TGs, the
enzymatically inactive band 4.2 protein and TG2 form
separate branches. The TG5/TG7 and TG3/TG6 pairs, each
encoded by genes located closely together on the same
chromosomes, are most closely related. A closer inspection
reveals that the frog sequences marked xTG5 and xTG6 in
Fig. 1f have ambivalent characteristics, and depending on
the settings of alignment parameters could be also regarded
as xTG7 and xTG3, respectively. Similarly, two bird
sequences are predicted, which share characteristics of the
TG5 and TG7 families. These data suggest that TG5/TG7
and TG3/TG6 arose from tandem gene duplication. We
have previously proposed that two genome duplications in
Fig. 1 Analysis of human TGM6 gene products. a Size of transcripts
expressed in H69 cells. Northern blot containing 5 lg of poly(A?)
RNA from H69 cells that was probed with a 0.7 kb antisense RNA
corresponding to the two C-terminal b-barrel domains of TG6. The
migration position of RNA size markers is indicated on the right and
the full-length TG6 transcript with an arrow. b RT-PCR analysis
identified two transcripts in H69 cells. PCR products spanning the
relevant region of the transcript (left) were separated in a 1% agarose
gel calibrated with the 1-kb ladder (right). These were identified by
sequencing to result from alternative splicing of exon 12 (Supple-
mental Fig. 3). c Schematic illustrating the relationship between gene
organization and protein structure in the TG family. TG4 contains an
additional exon, exon 1B, within intron 1 (Cho et al. 2010) that can
differentially be spliced in and encodes 45 amino acids. The band
4.2L variant contains an extended exon 1 (hatched box) (Sung et al.
1992). Variability in the 50 UTR has been reported in several TGM
genes but does not alter the sequence of the protein encoded.
Polyadenylated transcripts for TG6 isolated from H69 cells (hTG6)
and mouse brain (mTG6) are shown underneath: L denotes full-length
TG6, S TG6 lacking exon 12, d3 TG6 lacking exon 3 and d3,4 TG6
lacking exon 3 and 4. d Detection of TG6 in extracts of human
keratinocytes (lane 1) or HEK293 cells transfected with hTG6-L (lane
2) or hTG6-S (lane 3) expression constructs by Western blotting.
10 lg extracted protein was separated by SDS–PAGE under reducing
conditions, transferred to nitrocellulose membranes and labelled with
antibodies to TG6. Mr standards are indicated on the left. Keratino-
cytes express TG6-L but not TG6-S indicating that alternative
splicing is cell-type dependent. e Transamidation activity of
recombinant hTG6-L. The time-course for the incorporation of
biotin-x-cadaverine into N,N-dimethylcasein with different concen-
trations of TG6 or TG2 was determined. Activity was Ca2?-
dependent and maximal at [Ca2?] [ 1 mM (data for TG6 shown in
insert). The data are shown as mean ± SD. f Protein sequence
relationship of TGs. The dendrogram is based on a multiple sequence
alignment of TGs including coagulation factor XIII a-subunit (F13A)
and eryhtrocyte protein band 4.2 (EB42) from various species
(c chicken, h human, m mouse, x frog, Xenopus tropicalis, z zebra
fish, Danio rerio, dr fruit fly, Drosophila melanogaster, hb honey bee,
Apis mellifera, hc horseshoe crab, Tachypleus tridentatus, gh grass
hopper, Schistocerca americana, hy hydra, Hydra magnipapillata, pw
pork worm, Trichinella spiralis, py Physarum polycephalum, sa sea
anemonae, Nematostella vectensis, sf starfish, Asterina pectinifera, ss
sea squirt, Ciona intestinalis). The TG6 branches adjacent to TG3 are
highlighted by an arrow. All sequences except for the human, mouse
and frog band 4.2 protein contain the Cys, His and Asp residues of the
catalytic triad
c
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early vertebrates may have given rise to ancestral TGM1,
F13A1, TGMn and TGM4 genes and the ‘TGMn’ branch
subsequently further specified through tandem duplication
to form the full complement of TG genes in mammals
(TG2/3/5-7/EPB42; Grenard et al. 2001). The observation
of four principle TG branches for the higher chordata is
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consistent with the hypothesis of at least one whole gen-
ome duplication occurring after the urochordate ascidian
Ciona intestinalis, as it has been proposed based on gen-
ome comparisons of ancestral vertebrates (Dehal and
Boore 2005). More than one TG genes are also present in
some protostome genomes. However, these appear to have
arisen from gene duplication during prototsome speciation
independent from evolution of the TGM genes found in
vertebrates.
TG6 architecture predicted by molecular modelling
Based on the high sequence similarity between TG6 and
TG3 (overall sequence identity: 50 with 59% within the
catalytic core domain), we used the high-resolution X-ray
derived human TG3 structure (activated form with three
bound calcium ions) as a template for generating a model
of human TG6-L (Fig. 2a). The flexible solvent exposed
loop, which is not resolved in the X-ray structure connects
the last a-helical region of the catalytic core to the first
b-strand of the b-barrel 1 domain. The active site catalytic
triad residues C274, H333 and D356 are at the base of a
cavity, which is bound by the catalytic core and b-barrel 1
domains, and buried in a hydrophobic pocket, as in the case
of TG3 (Fig. 2b). Consistent with biochemical data and the
interpretation of the TG3 structure (Folk and Chung 1973;
Ahvazi et al. 2002; Ahvazi and Steinert 2003), it can be
assumed that the sulfhydryl group of C274 can form a
thiolate-imidazolium ion pair with H333. The second
nitrogen atom of the H333 ring is in hydrogen-bonding
distance to the side chain oxygen atom of D356. The indole
rings of the two tryptophan residues W238 and W330 are
buried near the surface as in TG3 (W236, W327). It has
been proposed that as a suitable glutamyl substrate
approaches, an oxyanion intermediate forms with the for-
mer tryptophan, which results in break-down of the sub-
strate to release NH3 and forms a thiol-acyl intermediate
with the enzyme. This intermediate is attacked by the
e-amine of a lysyl substrate to form another tetrahedral
oxyanion intermediate with the latter tryptophan resulting
in a cross-linked product (Pedersen et al. 1994). As in the
TG3 structure, the corresponding hydroxyl oxygen of Y538
from the b-barrel 1 domain is within hydrogen-bonding
distance of C274 and W238 and is located in the loop of
the sequence motif I536–T539 that obstructs the entrance
to the active site. The pair of serine residue S469;S470 in
TG3, which serve as cleavage site for proteolytic activation
by cathepsin L (Cheng et al. 2006), is not found in TG6
though cleavage by another enzyme cannot be ruled out.
However, TG6 has a high specific activity in the absence of
proteolytic processing (Fig. 1d). A redox-sensitive Cys
switch that is involved in oxidative inactivation of TG2
through formation of a vicinal disulfide bond (Cys370–
Cys371) (Stamnaes et al. 2010a) is not replicated in TG6 in
the same form as Cys230 is replaced by a serine residue.
Nevertheless, TG6 is profoundly sensitive to oxidative
inactivation.
Regulation of TG6 by co-factors
It is well established that transamidation activity of TGs
requires binding of calcium ions (Folk and Chung 1973).
As expected, activation of TG6 requires Ca2?-binding and
TG6 was found to display a similar concentration-
dependence for activation as TG2 (Fig. 1e). In the case of
factor XIII a, the activated enzyme contains a single
calcium ion in a position near to the catalytic site (Fox
et al. 1999) though its binding does not markedly alter the
structure. For the zymogen form of TG3, a single tightly
bound calcium ion has been found, but two further ions
are bound upon proteolytic activation (Ahvazi et al.
2002). In our model of TG6, the highest affinity binding
site 1 observed for TG3 is well conserved bringing the
main chain carbonyl oxygen atoms of A223, N226, N228
and the side chain oxygens of N226, and D230 into
coordinating distance of the TG3 inferred calcium ion
position (Fig. 2c). A second calcium-binding site can be
inferred to be formed by residues close to the C-terminal
end of the catalytic core domain adjacent to the loop
which joins the b-barrel 1 domain. The main chain oxy-
gen atom of T417, and side-chain oxygens of N396, E445
and E450 are in a position to coordinate a calcium ion. In
the case of TG3, calcium access to the related site in the
zymogen form is hampered by the flexible loop (residues
462–471), which must be cleaved to allow entry. We do
not yet know whether such a cleavage occurs in the case
of TG6, though it could be speculated that the 11 residues
longer loop might be more flexible to allow entry to this
site, and this is supported by the high specific activity of
the intact TG6 (Fig. 1e). A third calcium-binding site
reported for activated TG3 is found adjacent to the cat-
alytic triad histidine residue within a loop the position of
which is shifted upon activation. The residues involved in
calcium coordination are all conserved within the TG6
sequence and structural modelling suggests a corre-
sponding orientation with the main chain carbonyl of
S309 and side chain oxygen atoms of D303, D305, D327
and N307 as putative calcium acceptor sites.
It has been shown for TG2 (Achyuthan and Greenberg
1987; Im et al. 1990), TG3 (Boeshans et al. 2007) and TG5
(Candi et al. 2004) that enzymatic activity is inhibited by
purine nucleotides. Ca2?-binding and nucleotide binding
occur at different sites and stabilize distinct conformations
of TGs. The affinity of GTP is substantially reduced in the
presence of extracellular Ca2? concentrations allowing
enzyme activation. In contrast to ATP, the affinity for GTP
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and Mg-GTP is high and therefore of biological signifi-
cance. Besides inhibiting transamidation activity intracel-
lularly, independent functions of GTP binding and
hydrolysis in intracellular signalling have been proposed
for TG2 (Im et al. 1990; Stephens et al. 2004; Iismaa et al.
2009).
Fig. 2 Model of the structure of human TG6-L and its interaction
with nucleotides. a The overall structure as modelled based on the
calcium activated TG3 form is shown. Cylinders and arrows denote
a-helical and b-strand conformations, respectively. The four domains
(b sandwich, residues 3–136; catalytic core, res. 137–462; b-barrel 1,
res. 494–605; b-barrel 2, res. 606–706) are depicted in different
colours. The position of the three bound calcium ions of TG3 is
shown by numbered yellow spheres. The residues of the catalytic triad
are depicted in space-filling style. The flexible loop (res. 463–492)
connecting the catalytic core with the b-barrel 1 domain has been
deleted as the corresponding part is not resolved in the TG3 X-ray
structure. b The residues of the catalytic triad and the adjacent
tryptophan and tyrosine residues, the positions of which are proposed
to be modulated by calcium (yellow spheres) binding, are shown as
ball-and-stick and stick models, respectively. The side chain oxygen
of Y538 is in hydrogen-bonding distance to the sulphur atom of C274.
c Oxygen atoms of TG6 residues, which are within 3.5 A˚ distance of
the calcium ion sites of the TG3 template, are shown as red spheres.
Further calcium coordination could arise from water molecules not
included in the modelling. d Transamidation activity (measured as
isopeptide replacement activity) of TG6 (closed symbols; solid lines)
and TG2 (open symbols, dashed lines) was measured in the presence
of various concentrations of nucleotides, and half-maximum activity
is indicated by a dotted line: GTP, black; GTP in the presence of
1 mM Mg2?, orange; GTPcS, green; GDP, magenta; GMP, blue; and
ATP, red. Symbols indicate representative values of duplicate
independent measurements. e The putative nucleotide-binding pocket
was inferred from the GDP-bound TG2 structure. A semitransparent
surface showing the electrostatic potential (blue positive, red
negative) is overlaid over the residues surrounding a GDP molecule
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We therefore determined the transamidation activity
of TG6 in the presence of various nucleotides (Fig. 2d)
using a quenched fluorescent substrate, Abz-APE(c-cad-
Dnp)QEA, for real-time monitoring as suggested by
Lorand and co-workers (Parameswaran et al. 1997). Folk’s
work has shown that the reaction occurs in a two-step
mechanism whereby the active site thiol is transiently
acylated by the c-carboxamide group of the peptide-bound
glutamine to form a stable acyl-enzyme intermediate. The
second step involves either hydrolysis to convert Q to E or
aminolysis by reaction with a primary amine to form the
isopeptide bond and this is rate-limiting (Folk and Chung
1973). This reaction is reversible and steady-state kinetics
can be performed by coupling isopeptide hydrolysis to a
second reaction driven by an excess amine donor substrate.
Given that the reactive nucleophilic form of the substrate is
the neutral amine, maximum substrate conversion is
achieved with amines deprotonated at physiological pH
such as glycinemethylester or ethylene diamine (pKa \ 7)
(Leblanc et al. 2001). The sequence of the fluorescent
substrate is based on the amine acceptor site of osteonectin/
BM-40/SPARC for TG2 (Hohenadl et al. 1995). Never-
theless, the kinetic parameters given in Table 1 show that
this peptide is a better substrate for TG6 than for TG2.
When compared with TG2, a *50-fold higher concentra-
tion of GTP (200 lM) is required for half-maximal inhi-
bition of TG6, whereas for ATP (*1 mM) similarly high
concentrations are needed. The non-hydrolyzable GTP
analogue GTPcS is a more effective inhibitor than GTP as
has been reported for TG2 (Achyuthan and Greenberg
1987). Activity of TG6 is inhibited to a similar degree by
GTP and GDP both in the absence and presence of
1 mM Mg2?, but the affinity for GMP is low. Taken
together, these data suggest that TG6 has the potential to
function as a guanine nucleotide exchange factor in
receptor signalling similar to TG2.
Based on the GDP-bound form of human TG2 (PDB
code 1KV3, chain C, Liu et al. 2002), we modelled a
putative corresponding nucleotide-binding pocket between
the catalytic and b-barrel 1 domains (Fig. 2e). Such a TG6
GDP-binding site would be delineated by residues K170
and H171 from the catalytic domain, and K498 to P505 as
well as K600 to E605 from the b-barrel 1 domain. The
e-amino groups of lysine residues 170, 498, 500 and 600
envelop the phosphate groups of GDP, whereas V501–
P505 and L604 surround the guanine group which is
stacked by the imidazole ring of H171. In TG2, R478 and
R580 form two ion pairs with the GDP a- and b-phos-
phates. These residues are replaced by K500 and K600 in
TG6. S482 and Y583 of TG2, which form hydrogen bonds
with the N1 and N2 atoms of the guanine base are replaced
by P505 and T603, respectively, in TG6 of which the main
chain oxygen of T603 hydrogen bonds to N1 and N2, and
its oxygen to O6. Although the fold around a putative GDP
molecule can be well adopted by TG6, the reduced number
of interactions could be the cause for the observed decrease
in nucleotide affinity (Fig. 2d).
Substrate specificity
There is a large degree of overlap in glutamine donor
substrates of TG6, TG3, and TG2. On the level of fine
specificity, however, clear differences exist. In peptides,
TG2 has a highly sequence-dependent targeting (Gorman
and Folk 1984; Vader et al. 2002; Hitomi et al. 2009),
whereas TG6 shows tolerance to a broader spectrum of
sequence changes in the neighbouring amino acids
(Stamnaes et al. 2010b). The most significant influence on
substrate properties is exerted by proline residues. None
of the enzymes can modify glutamine residues directly
followed by proline (-QP-), whereas proline at position
?2 (-QXP-) exerts a positive influence. Furthermore,
while all three enzymes readily target -PQ- sequences,
proline in position -2 (-PPQ-) has a detrimental effect on
recognition by TG2, but not TG6 or TG3. An indication
that different positions may have a greater impact on
Fig. 3 TG6 expression in mouse development. a Amplification of
TGs from mouse whole brain cDNA. Products amplified with primers
specific for TG1 (lane 1, 182 bp), TG2 (2, 177 bp), TG3 (3, 157 bp),
TG5 (5, 135 bp), TG6 (6, 171 bp), and TG7 (7, 126 bp) could be
detected but not TG4 (lane 4), factor XIII a-subunit (lane 8) and band
4.2 protein (lane 9). Products were analysed by electrophoresis in a
1% agarose gel calibrated with the 1-kb ladder. b TG6 expression in
the developing and mature mouse brain. In situ hybrization was
carried out with antisense (b) and sense (c) DIG-labelled TG6 RNA
probes on serial sagittal sections of a newborn mouse or adult mouse
brain (dark brown labelling with alkaline phosphatase and NBT/
BCIP). A section stained with luxol fast blue/cresyl violet a shows the
myelin and nuclei of nerve cells. C cortex, Cer cerebellum, ChP
choroid plexus, Hip hippocampus, Mid mid brain, St striatum, Tha
thalamus. Higher magnification images demonstrate labelling of cells
in the cerebral cortex at P0 (d) and in mature brain (e) through layers
II–VI, in Purkinje cells of the cerebellum (g) and keratinocytes in the
epidermis and forming the hair shaft (h). Immunostaining of P0 serial
section with antibodies recognizing the hinge region of TG6 confirms
protein expression within the cell layers forming the motor cortex
(red brown labelling with HRP and AEC) (f) and cells within grey
matter of the spinal cord (FITC) (i). WM white matter, GM grey
matter. c Sections of mouse embryo at the indicated developmental
stages were hybrized with the antisense TG6 RNA probe. Images a–
c depict a sagittal section through the developing head and images d–
f a close-up of the telencephalon. A schematic illustrating the
development of the cerebral cortex together with hematoxylin/eosin
stained sections of the developing cerebral cortex at E11 and E16 is
given in g. The cortical plate (CP) which will give rise to the
multilayered neocortex (layers I–VI) develops between the marginal
zone (MZ) and subplate (SP) which is derived from the preplate (PP).
Pyramidal neurons within layer V/VI differentiate first and are
positive for b-tubulin III by E16. Immunostaining for TG6 labels CP
and layers V/VI of neocortex at E16 (g) whereas TG6 RNA
expression is predominant in CP (f). IZ intermediate zone, SVZ
subventricular zone, VZ ventricular zone
c
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substrate recognition by the different enzymes comes
from the observed differences in relation to altered pep-
tide length N- or C-terminal to the reactive glutamine
residue. TG6 and TG2 are profoundly sensitive to the
C-terminal sequence, whereas reactivity of TG3 with
peptide substrates is primarily influenced by the sequence
N-terminal to the glutamine residue (Stamnaes et al.
2010b). TG6 can both deamidate (Stamnaes et al. 2010b)
and transamidate (Fig. 1d) glutamine residues, but it has
not been determined yet for TG6 whether the type of
modification that occurs preferentially is influenced by the
sequence context as has been demonstrated for TG2
(Boros et al. 2006).
TG6 is associated with neuronal differentiation
in the central nervous system
RT-PCR from mouse brain cDNA using specific primers
for TG6 and also the other members of the TG family
revealed expression of TG1, TG2, TG3, TG5, TG6 and
TG7 (Fig. 3a). These results are consistent with demon-
stration of expression of TG1, TG2, TG3, and TG5 in the
brain (Kim et al. 1999; Bailey and Johnson 2004; Bailey
et al. 2004) and together with cell biological studies points
to a highly complex regulation of TG genes in the CNS. To
obtain a clearer understanding of TG6 expression on the
cellular level, in situ hybridisation was performed on sag-
ittal newborn mouse sections. An antisense RNA fragment
corresponding to the C-terminal end of TG6 was used as a
probe as this area has the least similarity between the dif-
ferent TGs and a similar human probe gave no cross-
hybridisation with other TG gene products in Northern
blotting. In situ hybridisation revealed that TG6 expression
is widespread in the brain (Fig. 3b), most prominently
within the cell layers containing the neuronal cell bodies of
the cerebral cortex (particularly layers II–IV containing
granular neurons and pyramidal cells) (image d), olfactory
lobe (data not shown; see Fig. 3c, image c) and the cere-
bellum (Purkinje cells) (image g). TG6 expression was
detected in the spinal cord (image i) and in the retinal cells
of the eye (data not shown). TG6 was expressed in tissues
other than the CNS, most prominently in the skin (image h)
and other stratified squamous epithelia. Interestingly, these
cells derive embryologically from a common ectodermal
progenitor. Immunolabelling with antibodies confirmed
TG6 protein expression (image f).
Given the prominent expression of TG6 in the CNS in
the developed organism, we were interested to identify
whether the induction of TG6 expression correlated with
any specific events in development. While the CNS is the
first organ system to develop and to differentiate, it is also
one of the last to be completed. The primary parts of the
mouse brain can be identified soon after the neural groove,
neural plate and head process stage at E7.5, and by day E14
has the typical anatomical layout of a mammalian brain.
The neocortex is a highly organized six-layered structure
that contains hundreds of different neuronal cell types and
various subsets of glia. Progenitors residing in the ven-
tricular zone produce the neurons of the different neocor-
tical layers in a tightly controlled temporal order between
about days E11 and E17.5 (Molyneaux et al. 2007). In situ
hybridisation was therefore carried out on stage E11, E13
and E16 embryos (Fig. 3c). The walls of the primitive
brain divide into an inner ependymal, an intermediate
mantel, and outer marginal layer by E10, whereby the
ependymal layer that ultimately forms the lining of the
ventricles of the brain is the thickest layer. At E11, active
proliferation of neuroblastic cells occurs in the walls of the
entire CNS and these begin to occlude some of the neural
cavities. Up to E11, the major neuroblastic activity is
occurring behind the hindbrain where cranial ganglia V to
IX develop. Little TG6 expression can be detected in the
brain at E11 while labelling can be seen in the developing
spinal cord (Fig. 3c, image a, arrow). By E13, TG6
expression is apparent in several parts of the brain and
strong expression can now be detected in regions under-
going neuronal differentiation such as the mesencephalon
(image b, arrow). From E13 to 16, the major neuroblastic
activity occurs in the telencephalon where cells from the
mantle layer migrate into the overlying marginal zone to
form the neocortex which will become the outer grey
matter of the cerebral hemispheres. At E13, TG6 expres-
sion is detected in a thin layer of the neocortex, presumably
progenitor cells constituting the preplate (image e). By
E16, TG6 is highly expressed in the outer layers of the
neocortex (image f). TG6 mRNA expression is most
prominent within the area of the cortical plate where
neuronal differentiation occurs to form layers II–IV (image
Table 1 Kinetic parameters of TG2 and TG6 for the replacement reaction of Abz-APE(c-cad-Dnp)QEA at 37C, pH 7.4, in the presence of an
excess glycinemethylester
vmax (M/s) kcat (/s) KM (M) kcat/KM (/M s)
TG2 0.83 ± 0.14 9 10-9 3.2 ± 0.5 9 10-3 110 ± 23 9 10-6 0.30 ± 0.07 9 102
TG6 2.6 ± 0.4 9 10-9 10.1 ± 1.6 9 10-3 49 ± 12 9 10-6 2.1 ± 0.6 9 102
Calculations were based on a molecular mass of 77 and 79 kDa for TG2 and TG6, respectively. The data are shown as mean ± SD
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f). TG6 protein is most prominent within layers V/VI
where postmitotic neurons can be labelled for b-tubulin III
at this stage (image g). Induction of TG6 expression
appears to correlate both spatially and temporally with
neurogenesis. In contrast, in situ hybridisation with a TG5
antisense RNA probe showed widespread expression
throughout the CNS by E11 (data not shown).
Towards the latter stages of corticogenesis, astrocytes
differentiate from radial glia. To clarify whether TG6
expression was associated with neurogenesis or astrocyte
differentiation, progenitors were isolated from P0 stage
mouse cortex and expanded in suspension culture as
neurospheres (Murayama et al. 2002). To induce neuronal
differentiation, progenitors were seeded on a laminin-111
substrate in the absence of mitogen for 5 days and subse-
quently labelled for TG6 and cell lineage markers. Cells of
the neuronal lineage were identified using antibodies
against b-tubulin III (Tuj-1), astrocytes with antibodies to
glial fibrillary acidic protein (GFAP) and oligodendrocytes
with RIP-antibodies (Sergent-Tanguy et al. 2003). Immu-
nocytochemistry confirmed expression of TG6 in neuronal
cells and its absence from the astroglial and oligoden-
droglial lineage (Fig. 4a). To exclude de novo expression
of TG6 in neurons as a consequence of culture conditions,
freshly isolated cells from the cerebral cortex of newborn
mice were double-labelled with antibodies to TG6 and to
the above cell lineage markers and analysed by FACS. 81%
of cells were positive for TG6 and 58% for b-tubulin III,
with 99% of b-tubulin III positive cells also positive for
TG6. Physical parameters can be used to distinguish neu-
rons, astrocytes and microglial cells as they differ in size
and morphology (Sergent-Tanguy et al. 2003). Therefore,
we plotted forward scatter (FSC), representing cell size, as
a function of fluorescence intensity for TG6 labelling.
Within the broad distribution of cells expressing TG6, two
clusters of cells of different size were apparent and were
gated (Supplemental Fig. 4, R1 and R2). Further analysis
of gated cells for expression of cell lineage markers
showed that both clusters were exclusively positive for
b-tubulin III indicating that they are derived from the
neuronal lineage and represent different neuronal popula-
tions (Supplemental Fig. 4).
Neuro2A is a mouse neural crest-derived cell line that
has been extensively used to study neuronal differentia-
tion, and specification into different neuronal lineages is
possible (Tremblay et al. 2010). We initially confirmed
that non-lineage-specific differentiation in low serum
induced TG6 expression and subsequently used a number
of differentiation factors to induce lineage-specific dif-
ferentiation (Fig. 4b). Non-cholinergic differentiation with
neurotrophin NGF was associated with strong upregula-
tion of TG6. TG6 expression was also induced upon
dopaminergic differentiation using dibutyryl cAMP,
whereas TG6 was not upregulated in cells treated with
retinoic acid, a known inhibitor of dopaminergic differ-
entiation. Quantitative PCR indicated that TG6 expression
was upregulated twofold upon serum starvation and
fourfold by dibutyryl cAMP. Dopamine neurons are
formed in the olfactory lobe and retina during embryonic
development, two areas where strong TG6 expression was
seen in in situ hybridization (Fig. 3). However, the
highest level of TG6 expression in Neuro 2a cells was
observed upon induction of cell death by metal ion che-
lation suggesting that the strong TG6 expression observed
during cerebral cortex development may relate in parts to
association with programmed cell death rather than neu-
ronal differentiation.
Cerebellar ataxia as consequence of genetic defects
in TGM6 gene or acquired autoimmunity to TG6
Celiac disease (CD) is a common T cell-mediated auto-
immune disorder characterized by its linkage to specific
human lymphocyte antigen alleles, HLA-DQ2 and -DQ8
(Jabri and Sollid 2009). In susceptible individuals, con-
sumption of gluten triggers a CD4? T-cell response to
gliadin as well as a B cell response to gliadin and self
antigens. TG2 contributes to disease development in at
least two ways: first, by deamidating gluten peptides,
thereby increasing their reactivity with HLA-DQ2/DQ8,
which potentiates the T-cell response (Molberg et al. 1998;
Van de Wal et al. 1998). Second, TG2 is the major auto-
antigen targeted by the B cell response (Dietrich et al.
1997). Although the T-cell response in the mucosa of the
small intestine is the key player in disease development,
gluten sensitivity is a systemic disease and autoantibodies
may play a role in extraintestinal pathogenesis (Caja et al.
2011). This is supported by the recent demonstration of
circulation derived anti-TG3 autoantibodies inducing a
dermatitis herpetiformis-like pathology in human skin-
grafted SCID mice (Zone et al. 2011). Neurological
disorders have also been recognised as a form of extrain-
testinal manifestation of gluten sensitivity, with cerebellar
involvement (gluten ataxia) and peripheral nerve involve-
ment (gluten neuropathy) being the most common pre-
sentations (Hadjivassiliou et al. 2010). We have shown that
gluten ataxia patients develop autoantibodies that are spe-
cific to TG6 (Hadjivassiliou et al. 2008). Furthermore,
antibodies isolated from celiac disease patients are fre-
quently reactive with human and mouse neurons. However,
this neuronal reactivity is specific for antibodies that are
crossreactive between the closely related TG2, TG3 and
TG6 enzymes and is not mediated by TG2 as it is preserved
in a TG2-/- background (Boscolo et al. 2010). This
is consistent with TG2 being primarily associated with
the vasculature in non-disease brain (Aeschlimann and
Transglutaminase 6 173
123
Paulsson 1991; Hadjivassiliou et al. 2008; Boscolo et al.
2010) and suggests that TG6 may be the neuronal auto-
antigen recognised in these patients. To test whether
patient-derived autoantibodies directly contribute to
pathology we attempted passive disease transfer. Serum
immunoglobulin from gluten ataxia patients, as well as
clonal anti-TG immunoglobulins derived using phage dis-
play, caused deficits in motor coordination but not anxiety
when injected intraventricularly in mice (Boscolo et al.
2010). The fact that isolated anti-TG immunoglobulins
induce dramatic ataxia-like deficits in mice indicates
selective neurotoxicity of anti-TG antibodies once exposed
to the CNS and suggests that antibodies may play a role in
disease transfer to the CNS. However, both scFv crossre-
active between different TGs and TG2-specific scFv
compromised motor coordination in mice.
Fig. 4 a Confirmation of neurons as the primary source for TG6
expression in the mouse cerebral cortex. Progenitor cells from
newborn mouse forebrain were grown as neurospheres and subse-
quently differentiated by culture in defined medium for 5 days on a
laminin-111 substrate and double stained for TG6 (TRITC) and
different cell markers (FITC): b-tubulin III isoform for neurons (a),
GFAP for astrocytes (b, c). Co-expression of TG6 with b-tubulin III is
highlighted by colour mixing (yellow, a). TG6 shows discrete
subcellular distribution in large protein complexes or vesicles
surrounding the nucleus and also in neurites (d, arrows). Left images
in a, b and inset in d provide DIC images of the field of view shown
under fluorescence illumination. Size bar 40 lm (a). b TG6 expres-
sion is upregulated concomitant with differentiation of Neuro 2a
mouse neuroblastoma cells. Neuro 2a cells were grown with 10%
FCS (a) or induced to differentiate by serum starvation (0.5% FCS)
(b) or serum starvation in combination with NGF (50 ng/ml) (c) or
dibutyryl cAMP (1 mM) (d) stimulation. After 3 days, cells were
labelled with antibodies to TG6 (alexa fluor 568, bottom panels) and
nuclei counterstained with Hoechst 34580. Upper panels provide DIC
images of the field of view to illustrate changes in cell morphology.
Size bar 10 lm (a)
174 H. Thomas et al.
123
Cerebellar ataxias are a complex and heterogeneous
group of neurodegenerative diseases characterized by
progressive imbalance and limb movement deficits. About
20% of cerebellar ataxias display a familial inheritance
pattern. So far, 30 different genetic loci have been linked to
different SCA subtypes and 19 causative genes identified.
Among those are CAG repeat expansion diseases including
SCA1–3, 6–8, 12, 17, 31 and DRPLA and non-repeat
mutations such as SCA 5, 11, 13–16, 27 and 28. A recent
paper identified mutations in TGM6 in two Chinese fami-
lies with autosomal dominant ataxia using linkage analysis
and exome sequencing (Wang et al. 2010). Taken together
with our demonstration of neuronal expression of TG6 and
the presence of autoantibodies to TG6 in immune-mediated
ataxia, this suggests that TG6 may play an important role in
neurons involved in motor control. The mutations identi-
fied in TGM6 are single nucleotide exchanges leading to
alteration of amino acid residues that are strictly conserved
in TG6 among different species (D327G, L517W). Struc-
tural modelling suggests that the former substitution could
interfere with Ca2? binding at site 3 (Fig. 2c) and may
therefore compromise enzyme activation, whereas the
deleterious effect of the latter substitution remains obscure.
It is also not clear why mutation of a single allele should
produce a dominant ataxia phenotype. Haploinsufficiency
is possible but one might also speculate that the problem is
unrelated to the catalytic function and could be caused by
difficulties in folding of mutant proteins and this may
ultimately be neurotoxic. It is also interesting to note that
alternative splicing or mutations in TG2 that affect its
regulation by GTP have been shown to have dramatic
effects on neuronal differentiation and to be pro-apoptotic
in different cell types (Antonyak et al. 2006; Tee et al.
2010).
In order to gain a better understanding of the TG6-
related pathology further work needs to address the phys-
iological function of TG6 in the CNS. Given that TG6
similar to TG2 is a protein that can be detected in the cell
cytosol as well as at the cell surface it may have inde-
pendent intra- and extracellular functions that may employ
the enzyme’s ability to bind GTP or act as a Ca2?-depen-
dent crosslinking enzyme, respectively. Recent progress in
the development of more isozyme-specific inhibitors may
facilitate the elucidation of the context within which TG6
is activated and plays a critical role.
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